The Fellow on Call: The Heme/Onc Podcast

Dr. Jacob Hall, Senior Radiation Oncology resident and Chief Resident at UNC-Chapel Hill, discusses patient selection and key terms in radiation oncology for prostate cancer. They cover the role of radiation in metastatic disease, brachytherapy, and the use of proton therapy. The podcast also includes humorous camping stories and discussions on treatment options and hypofractionation in prostate cancer radiation therapy.

Dr. Sanjay Patel, a urologic oncologist, joins the hosts to discuss prostate cancer management. They cover topics such as determining biopsy candidacy, the role of MRI in diagnosis, steps involved in a biopsy, and when additional imaging is needed. They also explore surgical approaches, when pelvic lymph node dissection is recommended, and active surveillance. The podcast provides valuable insights into the management of localized prostate cancer.

In this podcast, Vineetha Thomas, a clinical pharmacist specializing in genitourinary oncology, discusses the selection of drugs for prostate cancer, their side effects, and the role of chemotherapy. They also explore specific medications like prednisone, sipuleucel-T, radium 223, and lutetium-177. Additionally, they examine the importance of monitoring bone health in prostate cancer patients and the role of clinical pharmacists in prostate cancer treatment.

Prostate cancer is a prevalent concern for men, and this discussion dives into its complexities. Screening methods and controversial PSA testing are highlighted. The podcast also covers risk stratification using Gleason scores and staging. Local treatment options—from active surveillance to surgery—are explored. Key terminologies, such as castrate-sensitive and castrate-resistant states, are defined. The hosts set the stage for upcoming conversations with experts in the field, ensuring listeners are well-informed.

Pharmacist Renee McAllister discusses managing extravasation accidents, pharmacy operations, ideal body weight vs. AUC, giving G-CSF, and supportive care tips in hematology and oncology. They also emphasize the importance of staffing and safety checks in administering inpatient chemo, relying on primary sources for drug information, and the role of pharmacists in chemotherapy management.

The podcast discusses the basics of pharmacology in oncology, including the differences between irritants and vesicants, the need for central access in patients receiving therapy, and an overview of chemotherapy side effects.

The hosts discuss the importance of understanding chemotherapy fundamentals, counseling patients, and administering drugs. They explore treatment regimens, valuable resources, and the three main categories of chemotherapy: cytotoxic, immune, and targeted therapy. The chapter also covers important aspects of chemotherapy and previews upcoming topics.

Explore warfarin and enoxaparin failure in the context of anticoagulation. Discuss alternative options for patients with anti-phospholipid antibody syndrome (APLS) whose warfarin treatment failed. Learn about distinguishing new and residual clots on imaging and the implications. Understand APLS, its impact on lab testing, and accurate diagnosis. Explore the correlation between INR values and factor 10 activity in patients with lupus anticoagulants.

This podcast discusses the workup for anticoagulation failure, focusing on DOAC failure. They explore challenges and considerations, including verifying blood thinner levels, assessing patient adherence, and exploring anatomic reasons for clot formation. They also discuss alternative anticoagulants like warfarin.

This podcast dives deep into the management of relapsed diffuse large B-cell lymphoma, exploring innovative treatments like selective antibodies against CD19. The discussions highlight exciting alternative therapies, including loncastuximab and combination regimens with tafacitimab and lenalidomide. Listeners hear about the promising results from clinical trials and the evolving strategies post-CAR-T therapy. It also evaluates the potential of allogeneic transplants in DLBCL management, painting a hopeful future for lymphoma treatments.